

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

Stem Cell Transplant Weekly Conference - Journal Club - The Costs of Injectable Medications in the United States: Financial Bankruptcy for Cancer Patients and Moral Bankruptcy for the Healthcare System -CID #62774 – 62774-59351

Date: May 1, 2024

Time: 4:00 PM-5:00 PM

UH Cleveland Medical Center

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify the costs and payers in cancer case in the United States.
- 2 Explain the financial conflicts of interest between patients and clinics/hospitals.
- 3 Review the current policy landscape for payment reform to reduce financial toxicity of injectable medications.

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity’s planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Bryan Hambley, MD	Faculty	Nothing to disclose - 04/21/2024
Brenda Cooper, MD	Course Director	Nothing to disclose - 03/14/2024
Benjamin Tomlinson, MD	Other Planning Committee Member	Consulting Fee-Chimerics Speakers Bureau-BMS - 06/29/2023
Molly Gallogly, MD, PhD	Other Planning Committee Member	Consulting Fee-Incyte Speakers Bureau-Lilly Honoraria-MJH Life Sciences Consulting Fee-Citrus Health Group (Relationship has ended) Consulting Fee-The Dedham

PRESENTED BY:



SPONSORED BY:



SCHOOL OF MEDICINE
CASE WESTERN RESERVE
UNIVERSITY

		Group (Relationship has ended) - 06/21/2023
Leland Metheny, MD	Other Planning Committee Member	Speakers Bureau-Incyte Advisor-Bristol-Myers Squibb (Relationship has ended) Advisor-Gamida (Relationship has ended) - 07/06/2023
Lauren Brister, MSN, APRN-CNP	Other Planning Committee Member	Nothing to disclose - 06/30/2023
Jerries Kort, MD	Other Planning Committee Member	Nothing to disclose - 02/02/2024
Melissa Copley, PharmD	Other Planning Committee Member	Nothing to disclose - 06/05/2023
Frank Oley, PharmD	Other Planning Committee Member	Nothing to disclose - 05/04/2023
Koen van Besien, MD, PhD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds-Hemogenyx Stocks or stock options, excluding diversified mutual funds-Avertix Advisor-autolus Advisor-ADC Therapeutics Advisor-intellia (Relationship has ended) Advisor-morphosys (Relationship has ended) Advisor-crispr (Relationship has ended) Advisor-incyte (Relationship has ended) Advisor-adbio - 11/30/2023
James J Ignatz-Hoover , MD, PhD	Other Planning Committee Member	Nothing to disclose - 01/30/2024